Taking Control Of Our Destiny: Biocon Biologics CEO Tambe Celebrates European Viatris Integration
Fresh Opportunities Loom, With Seven Biosimilars Already In Europe And Three On The Way
With Biocon Biologics having previously integrated its acquisition of Viatris’s biosimilars business in emerging markets and North America, the firm has now completed integration in Europe. In an exclusive interview, CEO Shreehas Tambe tells Generics Bulletin what this means for the company and reveals the opportunities it perceives ahead.
